Total Funding
17
Total FundingDebt Financing raised
Growth Score
pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
630112
AesRx is a biopharmaceutical company dedicated to the development of two novel drugs, Aes-103 and Aes-210, which targets orphan diseases.
Acquired by 
Baxter International
About the Company
AesRx (ǽs-r-ex) is a biopharmaceutical company dedicated to the development of two novel drugs, each of which targets an orphan disease. AesRx's lead program, Aes-103, is a potential breakthrough in the treatment of sickle cell disease. Sickle cell disease is a recessive disorder of the hemoglobin which can cause red blood cells to deform
into rigid sickle shapes that block capillaries and other small blood vessels. This blockage can lead to a wide range of serious, sometimes life-threatening, conditions including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage to tissues and organs.
